Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body's immune response and can destroy healthy tissue in certain patients.
Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor approved in the United States, European Union, Canada and Australia as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.
| Contact Details: |
| 352 Knotter Drive |
| Cheshire |
| |
| 06410 |
| United States of America |
| Tel: | 203 272 2596 |
| Fax: | 203 772 3655 |
| Email: | alexion.europe@alxn.com |
| WWW: | www.alexionpharm.com/
|
| |
Recent Publications by Alexion Pharmaceuticals Incorporated: |  |
Importance of technical operations: lessons from evolving biotherapeutics production methods.
Research and development connect technology and innovation to product... | 22nd September, 2009
| Fermentation and Cell Culture Development, Technical Operations, Alexion
| Trends Biotechnol. 2009 Nov;27(11):612-4. Epub 2009 Sep 16.
DOI Direct Link |
Kinetic analysis of a monoclonal therapeutic antibody and its single-chain homolog by surface plasmon resonance.
Monoclonal antibodies (mAbs) and antibody fragments have become an... | 2nd September, 2009
| Alexion Pharmaceuticals, Cheshire, CT 06410, USA.
| Anal Biochem. 2009 Aug 29.
DOI Direct Link |
C5 blockade with conventional immunosuppression induces long-term graft survival in presensitized recipients.
We explored whether a functionally blocking anti-C5 monoclonal antibody... | 4th July, 2008
| Alexion Pharmaceuticals, Inc., Cheshire, CT, USA.
| Am J Transplant. 2008 Jun;8(6):1129-42. Epub 2008 Apr 29.
DOI Direct Link |
Characterization of cartilage from H-transferase transgenic pigs.
Cartilage engineering is the object of intense research as a result of... | 25th June, 2008
| Department of Molecular Sciences, Alexion Pharmaceuticals, Inc, Cheshire,
| Transplant Proc. 2008 Mar;40(2):554-6.
DOI Direct Link |
Mass spectrometry and HPLC with fluorescent detection-based orthogonal approaches to characterize N-linked oligosaccharides of recombinant monoclonal antibodies.
A number of HPLC and mass spectrometric techniques are used to... | 5th June, 2008
| Alexion Pharmaceuticals, Cheshire, CT, USA.
| Methods Mol Biol. 2008;446:347-61.
DOI Direct Link |
→View more Alexion Pharmaceuticals Incorporated research publications. |
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 14 individuals from Alexion Pharmaceuticals Incorporated using this service.
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 539 times since April 2007, the link to the organisation's website has been followed 68 times
Recent Search Terms used to find this page: Alexion Pharmaceuticals | alexion pharmaceuticals contact | Kinetic analysis of a monoclonal therapeutic antibody and its single-chain homolog by surface plasmon resonance pdf | C5 blockade with conventional immunosuppression induces long term graph survival in presensitized recipients | alexion milano | .
Search for more companies in Cheshire
Search for more companies in
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
Alexion Pharmaceuticals Incorporated
